

## BENZOXAZOLE: THE NUCLEUS OF DIVERSE BIOLOGICAL ACTIVITIES

B. Shrivastava, Vandana Sharma\*, Priyanka Lokwani

School of Pharmaceutical Sciences, Jaipur National University, Jaipur-302025, India.

*Corresponding author e-mail:* vandana\_mpharma@yahoo.co.in

---

### Summary

A series of analogue and derivatives of heterocyclic bearing nitrogen, oxygen and oxazole moieties constitutes the core structure of a several biological active compounds. Oxazole containing heterocyclic compounds plays an important role in medicinal chemistry and exhibit wide range of biological activities. Benzoxazole Nucleus have been reported various types of biological activities such as Antidepressant, Antibacterial, Antifungal, Antiinflammatory, Analgesic and Anticancer.

**Keywords:** Benzoxazole, antimicrobial, analgesic and anti inflammatory, anti hyperglycemic, anticancer, melatoninergic.

---

### Introduction

The small and simple benzoxazole nucleus is present in compounds involved in research aimed at evaluating new products that possess interesting biological activities like antimicrobial, CNS activities, antihyperglycemic potentiating activity, analgesic and anti-inflammatory activity. Benzoxazole is used primarily in industry and research, and has no household use. Being a heterocyclic compound, benzoxazole finds use in research as a starting material for the synthesis of larger, usually bioactive structures. Benzoxazoles can be considered as structural isosteres<sup>1</sup> of the naturally occurring nucleic bases adenine and guanine, which allow them to interact easily with polymers of living systems<sup>23</sup>.

#### Chemistry of benzoxazole nucleus<sup>24</sup>:

Benzoxazole is an aromatic organic compound with a molecular formula  $C_7H_5NO$ , a benzene -fused oxazole ring structure, and an odor similar to pyridine.





Fig.1. Benzoxazole

**Table 1: Following table shows chemical characteristics of Benzoxazole**

IUPAC name	1-Oxa-3-aza-1H-indene
Molecular formula	$C_7H_5NO$
Molar mass	119.12 g/mol
Solubility in water	Insoluble
Physical state	white to light yellow solid
Melting Point	27-30 <sup>o</sup> C

**SYNTHESIS OF BENZOXAZOLE NUCLEUS :**

Batey carried out a copper catalyzed one-pot synthesis of benzoxazoles using bromoanilines and acyl halides in the presence of a base and a solvent giving intermediates which finally gave pure benzoxazoles (21–97%) isolated yields, exhibiting a broad range of biological activities. They can also be used as precursors in the synthesis of drugs<sup>25-27</sup>.

**Figure 2****MEDICINAL IMPORTANCE OF BENZOXAZOLE NUCLEUS**

During recent years there have been some interesting developments in the biological activities of benzoxazole derivatives. These compounds have special significance in the field of medicinal chemistry due to their remarkable pharmacological potentialities.

**Benzoxazole with antimicrobial activity:**

Elamin I Elnima<sup>1</sup> *et al* studied the *in vitro* antibacterial<sup>2</sup> and antifungal activities of six benzimidazole and benzoxazole derivatives. They were tested against standard strains and 59 clinical isolates. Of the six compounds, only two compounds (both benzoxazoles) were active, whereas the rest were devoid of any activity. Considerable growth inhibition of all of the standard strains, including fungi and gram-positive and gram-negative bacteria, resulted when they were treated with these compounds. Fifty-nine clinical isolates of *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* were tested for susceptibility to the two compounds. The

most susceptible were the *S. aureus* isolates. The two compounds were of comparable activity against all of the isolates, with compound (b) showing a slightly higher activity than compound (a). Their respective minimal inhibitory concentrations for 90% inhibition of *S. aureus* were 25 and 50  $\mu\text{g/ml}$ . The gram negative bacteria were resistant to the two compounds and required minimal inhibitory concentrations of 200  $\mu\text{g/ml}$  for a similar degree of inhibition.





Figure 3

**Esin Sener<sup>2</sup> et al** synthesized 5-amino -2-(p-substituted-phenyl) Benzoxazole derivatives. They were synthesized by heating 2, 4-diaminophenol with the appropriate carboxylic acids in the presence of polyphosphoric acid. 2-substituted benzoxazoles<sup>3</sup> were prominently studied trusting that this position is decisive for the biological activity whereas position 5 prevailing the intensity of activity. Benzoxazoprofen and zoxazolamin are also the kind of benzoxazole derivatives which are substituted at both 2 and 5 positions.




## 5-Amino-2-(p-Substituted-Phenyl) Benzoxazole Derivatives

Figure 4


Table-2

R	Acid used as starting compound
H	Benzoic acid
C <sub>2</sub> H <sub>5</sub>	p-Ethyl benzoic acid
Br	p-Bromo benzoic acid
F	p-Fluorobenzoic acid
N(CH <sub>3</sub> ) <sub>3</sub>	p-Dimethylaminobenzoic acid
NO <sub>2</sub>	p-Nitrobenzoic acid


**Ahmet Akin<sup>4</sup> et al** synthesized 2, 5 – disubstituted benzoxazoles and benzimidazoles in order to determine their antimicrobial<sup>5</sup> activities and feasible structure activity relationship. The synthesized compounds were tested in vitro against 3 gram positive, 3 gram negative, bacteria and a fungus *Candida albicans*.



(a) 5-nitro-2-cyclohexyl Benzoxazole




(b) 5-nitro-2-cyclohexylmethyl Benzoxazole



(c) 2-cyclohexyl Benzoxazole

Figure 5




(d) 5-chloro 2-cyclohexylmethyl Benzoxazole

Figure 6

(a) and (b) were found most active than the others against *Bacillus subtilis* at MIC value of 3.12 µg/ml and the compound (b) indicated significant antibacterial activity against the enterobacter *Pseudomonas aeruginosae*. The compound (a), (c), (d) also exhibit antimycotic activity against *C.albicans*.

**P.Kohli<sup>6</sup> et al** synthesized Arylidenes of thiazolidines<sup>7</sup> with Mercaptobenzoxazole, namely [(aryl-4-oxo-1,3-thiazolidin)-hydrazinoacetyl-mercaptobenzoxazole];(5-arylidene)-2-aryl-4-oxo-1,3-thiazolidin hydrazinoacetyl-mercaptobenzoxazole. Thiazolidinone moiety is well known for biological and pharmacological activities such as CNS stimulant, anthelmintic, antibacterial, antifungal, hypnotic, amoebicidal, mosquito repellent, analgesic, diuretics, anti-inflammatory, anticonvulsant, nematocidal, antitubercular, etc. 2-Mercaptobenzoxazole is also reported as a good medicinal as well as a biological agent. It has been found that thiazolidinon-arylidenes and 2-mercaptobenzoxazole when incorporated in one framework enhance the biological activity. Antimicrobial evaluation was done by agar dilution method against three pathogenic bacteria viz. *Bacillus subtilis*, *Escherichia coli* and *Klebsiella pneumoniae* and three pathogenic fungi viz. *Aspergillus niger*, *Candida albicans* and *Fusarium oxysporum*. Among new derivatives evaluated, the chloro derivatives exhibited higher potency as compared to the standard drugs streptomycin (for bacteria) and griseofulvin (for fungi) against the tested organisms.




Ar<sub>1</sub> = -C<sub>6</sub>H<sub>5</sub>, 2-ClC<sub>6</sub>H<sub>4</sub>, 3-ClC<sub>6</sub>H<sub>4</sub>

Ar<sub>2</sub> = -C<sub>6</sub>H<sub>5</sub>, 2-ClC<sub>6</sub>H<sub>4</sub>, 3-ClC<sub>6</sub>H<sub>4</sub>

**Figure 7**

**Jarmila Vinsova<sup>5</sup> et al** synthesized A series of lipophilic 2-substituted 5, 7-di-tert-butylbenzoxazoles by the reaction of 3, 5-di-tert-butyl-1, 2-benzoquinone with amino acids and dipeptides bearing N-terminal glycine. Dipeptides having other N-terminal amino acids undergo oxidative deamination. 5, 7-Di-tert-butylbenzoxazoles have shown activity against Mycobacterium tuberculosis and some nontuberculous strains where isoniazid has been inactive.

**Anil Kumar<sup>7</sup> et al** Synthesized new metal [Mg(II), Fe(II), Co(II), Ni(II), Zn(II) and Cd(II)] complexes from 2-(1'/2'-hydroxynaphthyl)benzoxazoles<sup>8</sup> and evaluate them for antimicrobial activity.




Where M=Fe, Co, Ni, Mg, Zn, Cd.

**Figure 8**

**Benzoxazole with CNS activity:**

**Nadeem Siddiqui<sup>8</sup> et al** synthesized a series of 5-Carbomethoxybenzoxazole Derivatives<sup>9</sup> by using methyl-p-hydroxybenzoate and evaluate for anticonvulsant activity and Neurotoxicity. The identity of the compounds was confirmed on the basis of their elemental analysis and spectral data.




R= H,2-Cl,4-Cl

R= H,2-OCH<sub>3</sub>,2-CH<sub>3</sub>,3-CH<sub>3</sub>,4-CH<sub>3</sub>

**Figure 9**

**Young Shin Chun<sup>10</sup> et al** synthesized Functionalized benzoxazole derivatives<sup>11</sup> based on the structural features of PIB and FDDNP, which show excellent binding affinities to aggregated A $\beta$ 42 fibrils. All the synthesized compounds were evaluated by competitive binding assay against aggregated A $\beta$ 42 fibrils using [<sup>125</sup>I]TZDM and displayed good in vitro binding affinities with K<sub>i</sub> values (0.47-15.3 nM) from subnanomolar to nanomolar range. Among them, two benzoxazoles having malononitrile and ester moieties at C-6 exhibited superior binding affinities (K<sub>i</sub> = 0.47 and 0.61 nM, respectively) to PIB (K<sub>i</sub> = 0.77 nM).



Where A= Malononitrile, Ethyl acetate or ester moiety.


**Figure 10**

**Sarangapani and Reddy<sup>22</sup>** synthesized isatin N-(2-alkyl-benzoxazole-5-carbonyl) hydrazones and screened them for analgesic, antidepressant<sup>23</sup> and H<sub>1</sub>-antihistaminic activities.


**Benzoxazole with antihyperglycemic potentiating activity:**

**Raok Jeon<sup>11</sup> et al** synthesized Benzoxazole Containing Thiazolidinedione Derivatives.

5-[4-[2-(Benzoxazol-2-yl-alkylamino) ethoxy] benzyl] thiazolidine-2, 4-diones have been prepared by Mitsunobu reaction of benzoxazolylalkylaminoethanol and hydroxybenzylthiazolidinedione.



**Figure 11**




R= Me, BRL 48432

**Figure 12**

Many of the [(heterocycloamino) alkoxy] benzyl]-2, 4-thiazolidinediones represented in Fig.2 have been already reported as potent antihyperglycemic agents. Of these Compounds, benzoxazole derivatives such as BRL 48482 (Fig.3) have been reported to have potent agonism to PPAR- $\gamma$  comparable to the well known antihyperglycemic agent, rosiglitazone.

**Benzoxazole with analgesic and anti-inflammatory activity:**

**Hakki Erdogan<sup>13</sup> et al** synthesized a novel series of Mannich bases<sup>14</sup> of 5-nitro-3-substituted piperazinomethyl-2-benzoxazinones. The compounds were examined for their *in vivo* antiinflammatory and analgesic activities in two different bioassays, namely, carrageenan-induced hind paw edema and p-benzoquinone-induced abdominal constriction tests in mice, respectively. In addition, the ulcerogenic effects of the compounds were determined. Among the tested derivatives most promising results were obtained for the compounds bearing electron-withdrawing substituents (F, Cl, COCH<sub>3</sub>) in the ortho/para position of the phenyl nucleus on the piperazine ring at 3 position of benzoxazinone moiety (a, b, c, d, e). The analgesic activities of all compounds are higher than their antiinflammatory activities.




5-nitro-3-piperazinomethyl-2-benzoxazinones

R= 4-C<sub>6</sub>H<sub>5</sub>F, 2-C<sub>6</sub>H<sub>5</sub>F, 4-C<sub>6</sub>H<sub>5</sub>Cl, 2-C<sub>6</sub>H<sub>5</sub>Cl, 4-C<sub>6</sub>H<sub>5</sub>COCH<sub>3</sub>

**Figure 13**

**H. OzanGulcan<sup>14</sup> et al** synthesized 4-(5-chloro-2-oxo-3H-benzoxazol-3-yl) butanamide derivatives and were screened for their analgesic and anti-inflammatory activities<sup>15</sup> as well as gastric ulceration potential in tested animals. 2-Oxo-3H-benzoxazole derivatives exhibit a broad range of biological properties including analgesic and anti-inflammatory activity. Among them, especially 3-substituted-2-oxo-3H-benzoxazoles are known to exhibit analgesic and anti-inflammatory properties. It has also been reported that mannich bases of 6-acyl-2-oxo-3H-benzoxazoles resulted in compounds with potent analgesic activity. Additional studies with some 3-aminoalkyl-2-oxo-3H-benzoxazole derivatives also demonstrated potent analgesic and anti-inflammatory Activity, and showed that these compounds exerted their *in vivo* activity by inhibiting the synthesis of prostaglandin E<sub>2</sub>. It was also demonstrated that the 6-acyl function attached to the benzene portion of 2-oxo-3H-benzoxazole ring was favourable for analgesic activity in these derivatives, and that (6-acyl-2-oxo-3H-benzoxazol-3-yl) alkanolic acids possessed potent analgesic and anti-inflammatory activity with reduced gastric toxicity. In general, most of the research on this class of compounds included substitutions on positions 3 and 6 of the 2-oxo-3H-benzoxazole nucleus. As a result, 2-oxo-3H-benzoxazoles bearing N-alkyl, N-acyl, N-diaminoalkyl and 6-acyl substituents were reported to have higher analgesic and anti-inflammatory activity.

**Benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors****Figure 14**

**Michele H. Potashman<sup>15</sup> et al** synthesised a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole **22** as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound **22** demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model ( $ED_{50} = 16.3$  mg/kg).


Benzoxazole <sup>22</sup>

Figure 15

#### Benzoxazole as glycoprotein IIb/IIIa inhibitors:

**Chu-Biao Xue<sup>16</sup> et al** synthesized a potent series of benzoxazole GPIIb/IIIa inhibitors<sup>17</sup>. The high potency of this series of compounds in the inhibition of platelet aggregation requires a benzamidine as the basic moiety and an  $\alpha$ -carbamate or sulfonamide substituted  $\beta$ -alanine as the acidic moiety.




Figure 16

#### Benzoxazole derivatives as novel melatoninerigic ligands:

**Sun LQ<sup>19</sup> et al** A novel series of benzoxazole derivatives was synthesized and evaluated as melatoninerigic ligands<sup>20</sup>. The binding affinity of these compounds for human MT (1) and MT (2) receptors was determined using 2-[(125) I]-iodomelatonin as the radioligand. This work also established the benzoxazole nucleus as a melatoninerigic pharmacophore.

#### Benzoxazole with anticancer activity:

**Kumar D<sup>20</sup> et al** report the activity of UK-1 (structurally unique bis (benzoxazole) natural product isolated from a strain of *Streptomyces*) against a wide range of human cancer cell lines. UK-1 displays a wide spectrum of potent anticancer activity<sup>21</sup> against leukemia, lymphoma, and certain solid tumor-derived cell lines, with IC (50) values as low as 20 nM, but is inactive against *Staphylococcus aureus*, a methicillin-resistant strain of *S. aureus*, or *Pseudomonas aeruginosa*. A series of analogues of the bis (benzoxazole) natural product UK-1 in which the carbomethoxy-substituted benzoxazole ring of the natural product was modified were prepared and evaluated for their anticancer and antibacterial properties. An analogue of UK-1 in which the carbomethoxy-

substituted benzoxazole ring was replaced with a carbomethoxy-substituted benzimidazole ring was inactive against human cancer cell lines and the two strains of *S. aureus*. In contrast, a simplified analogue in which the carbomethoxy-substituted benzoxazole ring was replaced with a carbomethoxy group was almost as active as UK-1 against the four cancer cell lines examined but lacked activity against *S. aureus*. Metal ion binding studies of these analogues demonstrate that they both bind Zn (2+) and Ca (2+) ions about as well as UK-1. The non-cytotoxic benzimidazole UK-1 analogue binds Mg (2+) ions 50-fold weaker than UK-1, whereas the simple benzoxazole analogue binds Mg (2+) ions nearly as well as UK-1. These results support a role of Mg (2+) ion binding in the selective cytotoxicity of UK-1 and provide a minimal pharmacophore for the selective cytotoxic activity of the natural product.

#### **Benzoxazole with antitubercular activity:**

**Klimesova V<sup>21</sup> et al** synthesized a set of 2-benzylsulfanyl derivatives of benzoxazole and evaluated for their in vitro antimycobacterial<sup>22</sup> activity against Mycobacterium tuberculosis, non-tuberculous mycobacteria and multidrug-resistant *M. tuberculosis*. The lead compounds in the set, dinitro derivatives exhibited significant activity against both sensitive and resistant strains of *M. tuberculosis* and also against non-tuberculous mycobacteria. It was established that lower lipophilicity has significant contribution to activity. Dinitrobenzylsulfanyl derivative of benzoxazole represents the promising small-molecule synthetic antimycobacterials.

#### **Conclusion**

Modifications on the benzoxazole nucleus have resulted in a large number of compounds having diverse pharmacological activities. The synthesis, structures and biological activities of benzoxazole derivatives have long been focused of research interest in the field of medicine, due to potential activities exhibited by them. The biological profiles of these new generations of benzoxazoles represent much progress with regards to older compounds. Looking into the medicinal importance of benzoxazole moiety, it will be worthwhile to synthesize certain newer derivatives of benzoxazole and screen them for their biological activities<sup>28-30</sup>.

#### **References**

1. Elamin i. Elnima, M. Uppal Zubair, and Abdullah A. Al-Badr, Antibacterial and Antifungal Activities of Benzimidazole and Benzoxazole Derivatives: Antimicrobial Agents and Chemotherapy, Vol. 19, No. 1, Jan. 1981, p.29-32.
2. Esin Sener, Ismail Yalcin, Seckin Ozden and Tuncel Ozden ,Synthesis and Antimicrobial activities of 5-amino-2-(p-substituted-phenyl) Benzoxazole Derivatives, IL Farmaco,52(2), 1997,99- 103.
3. E.S Charles , V.K. Agrawal, S. Sharma and R.N Iyer , Synthesis of 2,5-disubstituted benzimidazoles as potential antihookworm and antimicrobial agents, Eur.J.Med.Chem.-Chemical Theraputica,5,435-438 .
4. Ahmet Akin and Nejat Ucarturk, Synthesis and Structure –Activity Relationships of Some 2, 5 Disubstituted Benzoxazoles and Benzimidazoles as Antimicrobial Agents , IL Farmaco, 52(2), 1997, 92-96.
5. Jarmila Vinsova, Vaclav Horak, Vladimir Buchta and Jarmila Kaustova , Highly Lipophilic Benzoxazoles with Potential Antibacterial Activity, Molecules 2005, 10, 783-793.
6. P. Kohli, S. D. Srivastava and S. K. Srivastava, Synthesis and Biological Activity of Mercaptobenzoxazole Based Thiazolidinones and Their Arylidenes, Journal of the Chinese Chemical Society, 54, 2007 1003-1010.



7. Anil Kumar and Devinder Kumar, Synthesis and antimicrobial activity of metal complexes from 2-(1'<sup>2</sup>'-hydroxynaphthyl) benzoxazoles, *Arkivoc* 2007 (xiv) 117-125.
8. N. Siddiqui, M. Sarafroz, M. Mumtaz Alam and Waquar Ahsan, Synthesis, Anticonvulsant and Neurotoxicity Evaluation of 5-Carbomethoxybenzoxazole Derivatives, *Acta Poloniae Pharmaceutica and Drug Research*, Vol. 65 No. 4, 2008, 449-455.
9. B.Gopalakrishna, V.J Rao, S. Bari, A.Venkatesham, M. Sarangapani, N.Raghuandan, B.Srinivas, *Indian Drugs* 6, 2005, 369.
10. Young Shin Chun, Soo Jeong Lim, Seung Jun Oh, Dae Hyuk Moon, Dong Jin Kim, Cheon-Gyu Cho, and Kyung Ho Yoo, Synthesis of Functionalized Benzoxazoles and Their Binding Affinities to A $\beta$ 42 Fibrils, *Bioorg Med Chem Lett.* 2004 Mar 8; 14(5):1197-2000.
11. Raok Jeon and SoYeon Park, Synthesis and Biological Activity of Benzoxazole Containing Thiazolidinedione Derivatives, *Arch Pharm Res* Vol 27, No 11, 2004, 1099-1105.
12. B.C Cantello, M.A Cawthorne, G.P Cottam, P.T Duff, D. Haigh, R.M Hindley, C.A Lister, S.A Snith, and P.L Thurlby, [[Omega-(heterocycllamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. *J. Med. Chem.*, 1994, 37, 3977-3985.
13. Meric Koksak, Nesrin Gokhan, Esra Kupeli, Erdem Yesilada, and Hakki Erdogan, Analgesic and Antiinflammatory Activities of Some New Mannich Bases of 5-Nitro-2-Benzoxazolinones, *Arch Pharm Res* Vol 30, No 4, 2007, 419-424.
14. H. Ozan Gulcan, Serdar Unlu, Erden Banoglu, M. Fethi Sahin, Synthesis of New 4-(5-Chloro-2-oxo-3H-benzoxazol-3-yl) butanamide Derivatives and Their Analgesic and Anti-Inflammatory Properties, *Turk J Chem* 27, 2003, 467-476.
15. Michele H. Potashman, James Bready, Angela Coxon, Thomas M. DeMelfi, Jr., Lucian DiPietro and Nicholas Doerr, Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors, *J. Med. Chem.*, 2007, 50 (18), pp 4351-4373.
16. Chu-Biao Xue, Maria Rafalski, John Roderick, Charles J. Eyermann, Shaker Mousa, Richard E. Olson and William F. DeGrado, Design, synthesis and *in vitro* activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors, The DuPont Merck Pharmaceutical Co., Experimental Station, Wilmington, DE 1980.
17. W. Calhoun, R.P Carlson, R. Crossley, L.J. Datko, S. Dietrich, K. Heatherington, L. A. Marshall, P.J Meade, A. Opalko, and R. G. Shepherd, Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. *J. Med. Chem.*, 38, 1995, 1473-1481.
18. G.Dannhardt and W. Kiefer, Cyclooxygenase inhibitors-current status and future prospects, *Eur. J. Med. Chem.*, 36, 2001, 109-126.
19. LQ Sun, J Chen, K Takaki, G Johnson, L Iben, CD Mahle, E Ryan, Design and synthesis of benzoxazole derivatives as novel melatoninergic Ligands, *Bioorg Med Chem Lett.*, 2004 Mar 8; 14(5):1197-2000.
20. D Kumar, MR Jacob, MB Reynolds and SM Kerwin, Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1, *Bioorg Med Chem.* 2002 Dec;10(12):3997-4004.
21. V. Klimesova, J. Koci, K. Waisser, J. Kaustova, U. Mollmann, Preparation and *in vitro* evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents, *Eur. J Med Chem.* 2009 May;44(5):2286-93.
22. M. Sarangapani and V. M. Reddy, Pharmacological screening of isatin-N-(2-alkyl benzoxazole-5-carbonyl) hydrazones, *Indian. J. Pharm. Sci.* 59, 1997, 105-109.
23. I. Oren, O. Temiz, I Yalcin, E. A. Sener, N. Altanlar, *Eur. J. Pharm. Sci* 1998, 7, 153-160.
24. J. Perregaard, J. Arnt, P. K. Bogeso, J. Hyttel and C. Sanchez, Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT<sub>2</sub> antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles. *J. Med. Chem.*, 35, 1992, 1092-1101

25. F. Rohet, C. Rubat, P. Coudert and J.Couquelet, Synthesis and analgesic effects of 3-substituted 4, 6-diarylpyridazine derivatives of the arylpiperazine class. *Bioorg. Med. Chem.*,5, 1997, 655-659
26. S. Unlu, S. N. Baytas, E. Kupeli and E.Yesilada , Studies on novel 7-acyl-5-chloro-2-oxo-3h-benzoxazole derivatives as potential analgesic and antiinflammatory Agents, *Arch Pharm. Pharm. Med. Chem.*, 336,2003, 310-321
27. M. C.Viaud, P. Jamoneau, C.Flouzat, J. G. Bizot-Espiard, B. Pfeiffer, P. Renard, H.Caignard, , G.Adam, and G. Guillaumet, , N-Substituted oxazolo[5,4-b]pyridin-2(1H)-ones: A new class of non-opiate antinociceptive agents. *J.Med. Chem.*, 38, 1995,1278-1286.
28. W.Von der Saal, J. P. Holck, W. Kampe, A. Mertens, and B.Muller-Beckmann , Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.*J. Med. Chem.*, 32, 1989, 1481-1496.
29. B. S. Furniss, A. J. Hannaford, P. W. G. Smith, A. R. Tatchell, Vogel's Text book of Practical Organic Chemistry, 5th ed., 2005, Pearson Education: Singapore, pp. 1077
30. <http://www.Wikipedia.html> accessed on 17 December 2009.